Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report
Introduction: Treatment strategies for metastatic renal cell carcinoma (mRCC) have advanced, and its prognosis has improved. However, the progression-free survival of patients with mRCC who have received prior treatment is approximately 8 months, and long-term responses are rare. We appli...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-03-01
|
| Series: | Case Reports in Oncology |
| Online Access: | https://karger.com/article/doi/10.1159/000545249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850133619741294592 |
|---|---|
| author | Shinichi Maruyama Masaru Kato Masaru Ishida Tatsuru Hiraga Hiroshi Kanno |
| author_facet | Shinichi Maruyama Masaru Kato Masaru Ishida Tatsuru Hiraga Hiroshi Kanno |
| author_sort | Shinichi Maruyama |
| collection | DOAJ |
| description |
Introduction: Treatment strategies for metastatic renal cell carcinoma (mRCC) have advanced, and its prognosis has improved. However, the progression-free survival of patients with mRCC who have received prior treatment is approximately 8 months, and long-term responses are rare. We applied therapeutic drug monitoring to a case of mRCC in which a long-term response of more than 3 years was achieved after the administration of cabozantinib as third-line treatment. Here, we report the changes in the blood concentration of cabozantinib. Case Presentation: The patient was a 67-year-old man who had received sunitinib as the first-line treatment and nivolumab as the second-line treatment for stage IV mRCC. However, the disease progressed, and cabozantinib (40 mg/day) was initiated. Three months after the initiation of cabozantinib, partial tumor shrinkage was achieved. In the sixth month, the dose was reduced to 20 mg/day because of severe palmar-plantar erythrodysesthesia syndrome and anorexia; however, further tumor shrinkage was achieved. Fifteen months after starting cabozantinib, the trough concentration of cabozantinib was 960 ng/mL. Thereafter, cabozantinib concentration was measured almost every month and was found to fluctuate between 583 and 1,938 ng/mL; tumor shrinkage was maintained even at 39 months. Conclusion: Cabozantinib provided long-term benefits for more than 3 years. We emphasize that the measurement of cabozantinib concentration in the blood may play a supporting role as an indicator of long-term response. |
| format | Article |
| id | doaj-art-cd8c03bb25fc4881ba426e61b65b4a89 |
| institution | OA Journals |
| issn | 1662-6575 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj-art-cd8c03bb25fc4881ba426e61b65b4a892025-08-20T02:31:55ZengKarger PublishersCase Reports in Oncology1662-65752025-03-0118150050710.1159/000545249Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case ReportShinichi MaruyamaMasaru KatoMasaru IshidaTatsuru HiragaHiroshi Kanno Introduction: Treatment strategies for metastatic renal cell carcinoma (mRCC) have advanced, and its prognosis has improved. However, the progression-free survival of patients with mRCC who have received prior treatment is approximately 8 months, and long-term responses are rare. We applied therapeutic drug monitoring to a case of mRCC in which a long-term response of more than 3 years was achieved after the administration of cabozantinib as third-line treatment. Here, we report the changes in the blood concentration of cabozantinib. Case Presentation: The patient was a 67-year-old man who had received sunitinib as the first-line treatment and nivolumab as the second-line treatment for stage IV mRCC. However, the disease progressed, and cabozantinib (40 mg/day) was initiated. Three months after the initiation of cabozantinib, partial tumor shrinkage was achieved. In the sixth month, the dose was reduced to 20 mg/day because of severe palmar-plantar erythrodysesthesia syndrome and anorexia; however, further tumor shrinkage was achieved. Fifteen months after starting cabozantinib, the trough concentration of cabozantinib was 960 ng/mL. Thereafter, cabozantinib concentration was measured almost every month and was found to fluctuate between 583 and 1,938 ng/mL; tumor shrinkage was maintained even at 39 months. Conclusion: Cabozantinib provided long-term benefits for more than 3 years. We emphasize that the measurement of cabozantinib concentration in the blood may play a supporting role as an indicator of long-term response. https://karger.com/article/doi/10.1159/000545249 |
| spellingShingle | Shinichi Maruyama Masaru Kato Masaru Ishida Tatsuru Hiraga Hiroshi Kanno Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report Case Reports in Oncology |
| title | Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report |
| title_full | Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report |
| title_fullStr | Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report |
| title_full_unstemmed | Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report |
| title_short | Therapeutic Drug Monitoring in a Patient with Metastatic Renal Cell Carcinoma Who Achieved Long-Term Response to Cabozantinib in Third-Line Treatment: A Case Report |
| title_sort | therapeutic drug monitoring in a patient with metastatic renal cell carcinoma who achieved long term response to cabozantinib in third line treatment a case report |
| url | https://karger.com/article/doi/10.1159/000545249 |
| work_keys_str_mv | AT shinichimaruyama therapeuticdrugmonitoringinapatientwithmetastaticrenalcellcarcinomawhoachievedlongtermresponsetocabozantinibinthirdlinetreatmentacasereport AT masarukato therapeuticdrugmonitoringinapatientwithmetastaticrenalcellcarcinomawhoachievedlongtermresponsetocabozantinibinthirdlinetreatmentacasereport AT masaruishida therapeuticdrugmonitoringinapatientwithmetastaticrenalcellcarcinomawhoachievedlongtermresponsetocabozantinibinthirdlinetreatmentacasereport AT tatsuruhiraga therapeuticdrugmonitoringinapatientwithmetastaticrenalcellcarcinomawhoachievedlongtermresponsetocabozantinibinthirdlinetreatmentacasereport AT hiroshikanno therapeuticdrugmonitoringinapatientwithmetastaticrenalcellcarcinomawhoachievedlongtermresponsetocabozantinibinthirdlinetreatmentacasereport |